{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,5]],"date-time":"2026-07-05T18:13:13Z","timestamp":1783275193593,"version":"3.54.6"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,1,7]],"date-time":"2025-01-07T00:00:00Z","timestamp":1736208000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,1,7]],"date-time":"2025-01-07T00:00:00Z","timestamp":1736208000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"the Affiliated Huaian No.1 People\u2019s Hospital of Nanjing Medical University","award":["QC2022018"],"award-info":[{"award-number":["QC2022018"]}]},{"name":"the Affiliated Huaian No.1 People\u2019s Hospital of Nanjing Medical University","award":["QC2022018"],"award-info":[{"award-number":["QC2022018"]}]},{"name":"the Affiliated Huaian No.1 People\u2019s Hospital of Nanjing Medical University","award":["QC2022018"],"award-info":[{"award-number":["QC2022018"]}]},{"name":"Huaian city Science and Technology Bureau project","award":["HAB2024002"],"award-info":[{"award-number":["HAB2024002"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"DOI":"10.1186\/s12885-024-13388-y","type":"journal-article","created":{"date-parts":[[2025,1,7]],"date-time":"2025-01-07T05:58:31Z","timestamp":1736229511000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Prognostic significance of CDK1 expression in diffuse large B-Cell lymphoma"],"prefix":"10.1186","volume":"25","author":[{"given":"Qiuni","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chuanyang","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yujie","family":"Xue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xue","family":"Gong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuye","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunling","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liang","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,1,7]]},"reference":[{"key":"13388_CR1","doi-asserted-by":"publisher","first-page":"1000460","DOI":"10.3389\/fgene.2022.1000460","volume":"13","author":"Z Li","year":"2022","unstructured":"Li Z, et al. Gene set-based identification of two immune subtypes of diffuse large B cell lymphoma for guiding immune checkpoint blocking therapy. Front Genet. 2022;13:1000460.","journal-title":"Front Genet"},{"key":"13388_CR2","doi-asserted-by":"crossref","unstructured":"Takahara T et al. The Immunology of DLBCL. Cancers (Basel), 2023. 15(3).","DOI":"10.3390\/cancers15030835"},{"issue":"1 Suppl 1","key":"13388_CR3","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1016\/j.bbmt.2007.10.020","volume":"14","author":"IS Lossos","year":"2008","unstructured":"Lossos IS. Diffuse large B cell lymphoma: from gene expression profiling to prediction of outcome. Biol Blood Marrow Transpl. 2008;14(1 Suppl 1):108\u201311.","journal-title":"Biol Blood Marrow Transpl"},{"key":"13388_CR4","doi-asserted-by":"crossref","unstructured":"Alduaij W et al. Molecular determinants of clinical outcomes in a real-world diffuse large B-cell Lymphoma Population. Blood, 2022.","DOI":"10.1182\/blood.2022018248"},{"issue":"15","key":"13388_CR5","doi-asserted-by":"publisher","first-page":"1396","DOI":"10.1056\/NEJMoa1801445","volume":"378","author":"R Schmitz","year":"2018","unstructured":"Schmitz R, et al. Genetics and Pathogenesis of diffuse large B-Cell lymphoma. N Engl J Med. 2018;378(15):1396\u2013407.","journal-title":"N Engl J Med"},{"issue":"5","key":"13388_CR6","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1038\/s41591-018-0016-8","volume":"24","author":"B Chapuy","year":"2018","unstructured":"Chapuy B, et al. Molecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomes. Nat Med. 2018;24(5):679\u201390.","journal-title":"Nat Med"},{"issue":"4","key":"13388_CR7","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1016\/j.ccell.2020.03.015","volume":"37","author":"GW Wright","year":"2020","unstructured":"Wright GW, et al. A probabilistic classification Tool for genetic subtypes of diffuse large B cell lymphoma with therapeutic implications. Cancer Cell. 2020;37(4):551\u2013e56814.","journal-title":"Cancer Cell"},{"key":"13388_CR8","doi-asserted-by":"crossref","unstructured":"Modi D, Potugari B, Uberti J. Immunotherapy for Diffuse Large B-Cell Lymphoma: Current Landscape and Future Directions. Cancers (Basel), 2021. 13(22).","DOI":"10.3390\/cancers13225827"},{"issue":"2","key":"13388_CR9","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1038\/nrd4504","volume":"14","author":"U Asghar","year":"2015","unstructured":"Asghar U, et al. The history and future of targeting cyclin-dependent kinases in cancer therapy. Nat Rev Drug Discov. 2015;14(2):130\u201346.","journal-title":"Nat Rev Drug Discov"},{"issue":"3","key":"13388_CR10","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1158\/2159-8290.CD-19-0528","volume":"10","author":"J Chou","year":"2020","unstructured":"Chou J, et al. Transcription-Associated cyclin-dependent kinases as targets and biomarkers for Cancer Therapy. Cancer Discov. 2020;10(3):351\u201370.","journal-title":"Cancer Discov"},{"key":"13388_CR11","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/j.bbrc.2021.02.117","volume":"550","author":"S Sunada","year":"2021","unstructured":"Sunada S, et al. CDK1 inhibitor controls G2\/M phase transition and reverses DNA damage sensitivity. Biochem Biophys Res Commun. 2021;550:56\u201361.","journal-title":"Biochem Biophys Res Commun"},{"issue":"9","key":"13388_CR12","doi-asserted-by":"publisher","first-page":"1743","DOI":"10.1007\/s12094-021-02575-z","volume":"23","author":"Z Huang","year":"2021","unstructured":"Huang Z, Shen G, Gao J. CDK1 promotes the stemness of lung cancer cells through interacting with Sox2. Clin Transl Oncol. 2021;23(9):1743\u201351.","journal-title":"Clin Transl Oncol"},{"key":"13388_CR13","doi-asserted-by":"publisher","first-page":"e925289","DOI":"10.12659\/MSM.925289","volume":"26","author":"Y Zou","year":"2020","unstructured":"Zou Y, et al. CDK1, CCNB1, and CCNB2 are prognostic biomarkers and correlated with Immune Infiltration in Hepatocellular Carcinoma. Med Sci Monit. 2020;26:e925289.","journal-title":"Med Sci Monit"},{"issue":"9","key":"13388_CR14","doi-asserted-by":"publisher","first-page":"2481","DOI":"10.1158\/0008-5472.CAN-20-3580","volume":"81","author":"X Lu","year":"2021","unstructured":"Lu X, et al. Integrated screens identify CDK1 as a therapeutic target in Advanced gastrointestinal stromal tumors. Cancer Res. 2021;81(9):2481\u201394.","journal-title":"Cancer Res"},{"issue":"8","key":"13388_CR15","doi-asserted-by":"publisher","first-page":"1251","DOI":"10.4161\/cc.24313","volume":"12","author":"A Hedblom","year":"2013","unstructured":"Hedblom A, et al. CDK1 interacts with RAR\u03b3 and plays an important role in treatment response of acute myeloid leukemia. Cell Cycle. 2013;12(8):1251\u201366.","journal-title":"Cell Cycle"},{"issue":"23","key":"13388_CR16","doi-asserted-by":"publisher","first-page":"14925","DOI":"10.1073\/pnas.222491799","volume":"99","author":"Z Qian","year":"2002","unstructured":"Qian Z, et al. Expression profiling of CD34\u2009+\u2009hematopoietic stem\/ progenitor cells reveals distinct subtypes of therapy-related acute myeloid leukemia. Proc Natl Acad Sci U S A. 2002;99(23):14925\u201330.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"13388_CR17","unstructured":"The Genotype-Tissue Expression (GTEx) project. Nat Genet. 2013;45(6):580\u20135."},{"issue":"7675","key":"13388_CR18","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1038\/nature24265","volume":"550","author":"T Tukiainen","year":"2017","unstructured":"Tukiainen T, et al. Landscape of X chromosome inactivation across human tissues. Nature. 2017;550(7675):244\u20138.","journal-title":"Nature"},{"issue":"Database issue","key":"13388_CR19","first-page":"D991","volume":"41","author":"T Barrett","year":"2013","unstructured":"Barrett T, et al. NCBI GEO: archive for functional genomics data sets\u2013update. Nucleic Acids Res. 2013;41(Database issue):D991\u20135.","journal-title":"Nucleic Acids Res"},{"issue":"8","key":"13388_CR20","doi-asserted-by":"publisher","first-page":"2151","DOI":"10.1038\/s41375-021-01285-3","volume":"35","author":"MY He","year":"2021","unstructured":"He MY, Kridel R. Treatment resistance in diffuse large B-cell lymphoma. Leukemia. 2021;35(8):2151\u201365.","journal-title":"Leukemia"},{"issue":"6","key":"13388_CR21","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1182\/blood-2013-09-524108","volume":"123","author":"Z Zhou","year":"2014","unstructured":"Zhou Z, et al. An enhanced International Prognostic Index (NCCN-IPI) for patients with diffuse large B-cell lymphoma treated in the Rituximab era. Blood. 2014;123(6):837\u201342.","journal-title":"Blood"},{"key":"13388_CR22","doi-asserted-by":"publisher","first-page":"753712","DOI":"10.3389\/fonc.2021.753712","volume":"11","author":"J Qi","year":"2021","unstructured":"Qi J, et al. Elevated lactate dehydrogenase levels display a poor prognostic factor for Non-hodgkin\u2019s lymphoma in Intensive Care Unit: an analysis of the MIMIC-III Database Combined with External Validation. Front Oncol. 2021;11:753712.","journal-title":"Front Oncol"},{"issue":"1","key":"13388_CR23","doi-asserted-by":"publisher","first-page":"1557","DOI":"10.1038\/s41467-020-15289-7","volume":"11","author":"M Yasukawa","year":"2020","unstructured":"Yasukawa M, et al. CDK1 dependent phosphorylation of hTERT contributes to cancer progression. Nat Commun. 2020;11(1):1557.","journal-title":"Nat Commun"},{"issue":"1","key":"13388_CR24","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1186\/s12957-020-01817-8","volume":"18","author":"J Li","year":"2020","unstructured":"Li J, et al. CDK1 and CDC20 overexpression in patients with colorectal cancer are associated with poor prognosis: evidence from integrated bioinformatics analysis. World J Surg Oncol. 2020;18(1):50.","journal-title":"World J Surg Oncol"},{"issue":"11","key":"13388_CR25","doi-asserted-by":"publisher","first-page":"2323","DOI":"10.1007\/s12094-021-02687-6","volume":"23","author":"J Tang","year":"2021","unstructured":"Tang J, et al. MiR-495-3p and mir-143-3p co-target CDK1 to inhibit the development of cervical cancer. Clin Transl Oncol. 2021;23(11):2323\u201334.","journal-title":"Clin Transl Oncol"},{"issue":"12","key":"13388_CR26","first-page":"7233","volume":"11","author":"HP Zheng","year":"2019","unstructured":"Zheng HP, et al. Integrated assessment of CDK1 upregulation in thyroid cancer. Am J Transl Res. 2019;11(12):7233\u201354.","journal-title":"Am J Transl Res"},{"issue":"8","key":"13388_CR27","doi-asserted-by":"publisher","first-page":"2955","DOI":"10.1172\/JCI43354","volume":"122","author":"HS Radomska","year":"2012","unstructured":"Radomska HS, et al. Targeting CDK1 promotes FLT3-activated acute myeloid leukemia differentiation through C\/EBP\u03b1. J Clin Invest. 2012;122(8):2955\u201366.","journal-title":"J Clin Invest"},{"key":"13388_CR28","doi-asserted-by":"crossref","unstructured":"Yang Y et al. DNMT3A Mutation-Induced CDK1 overexpression promotes leukemogenesis by modulating the Interaction between EZH2 and DNMT3A. Biomolecules, 2021. 11(6).","DOI":"10.3390\/biom11060781"},{"issue":"1\u20132","key":"13388_CR29","doi-asserted-by":"publisher","first-page":"147","DOI":"10.3109\/10428199909145714","volume":"35","author":"D Wolowiec","year":"1999","unstructured":"Wolowiec D, et al. CDK1 and cyclin A expression is linked to cell proliferation and associated with prognosis in non-hodgkin\u2019s lymphomas. Leuk Lymphoma. 1999;35(1\u20132):147\u201357.","journal-title":"Leuk Lymphoma"},{"issue":"9","key":"13388_CR30","doi-asserted-by":"publisher","first-page":"1085","DOI":"10.1517\/14728220903103833","volume":"13","author":"XF Zhao","year":"2009","unstructured":"Zhao XF, Gartenhaus RB. Phospho-p70S6K and cdc2\/cdk1 as therapeutic targets for diffuse large B-cell lymphoma. Expert Opin Ther Targets. 2009;13(9):1085\u201393.","journal-title":"Expert Opin Ther Targets"},{"issue":"11","key":"13388_CR31","doi-asserted-by":"publisher","first-page":"9217","DOI":"10.1002\/jcb.27189","volume":"119","author":"H Zou","year":"2018","unstructured":"Zou H, et al. miR-129 targets CDK1 and iASPP to modulate Burkitt lymphoma cell proliferation in a TAp63-dependent manner. J Cell Biochem. 2018;119(11):9217\u201328.","journal-title":"J Cell Biochem"},{"issue":"9","key":"13388_CR32","doi-asserted-by":"publisher","first-page":"4348","DOI":"10.1002\/cam4.2324","volume":"8","author":"H Zhao","year":"2019","unstructured":"Zhao H, et al. Study of the mechanism by which dinaciclib induces apoptosis and cell cycle arrest of lymphoma Raji cells through a CDK1-involved pathway. Cancer Med. 2019;8(9):4348\u201358.","journal-title":"Cancer Med"},{"issue":"5","key":"13388_CR33","doi-asserted-by":"publisher","first-page":"612","DOI":"10.1038\/s41374-018-0182-9","volume":"99","author":"T Nagato","year":"2019","unstructured":"Nagato T, et al. Cyclin-dependent kinase 1 and survivin as potential therapeutic targets against nasal natural killer\/T-cell lymphoma. Lab Invest. 2019;99(5):612\u201324.","journal-title":"Lab Invest"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-024-13388-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-024-13388-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-024-13388-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,7]],"date-time":"2025-01-07T18:02:21Z","timestamp":1736272941000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/s12885-024-13388-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,7]]},"references-count":33,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["13388"],"URL":"https:\/\/doi.org\/10.1186\/s12885-024-13388-y","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,7]]},"assertion":[{"value":"12 June 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 December 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 January 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All experiments on humans and\/or the use of human tissue samples were performed in accordance with relevant guidelines and regulations. Informed consent from all of the participants in the study was obtained. The research conducted on human participants underwent a thorough evaluation and received approval from the Institutional Review Board (IRB) of the Affiliated Huaian No.1 People\u2019s Hospital of Nanjing Medical University(KY-2023-181-01).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"20"}}